News Sanofi, Regeneron aim to undercut rivals with new RA drug New drug will be sold at around 30% discount to rivals.
News AbbVie’s 8-week hepatitis C drug granted early access in UK AbbVie’s hepatitis C drug granted early access in UK
News AbbVie takes aim at Gilead and BMS with 8-week hep C treatme... Trial backs patient-friendly regime in tough to treat strain.
News Doubts over AbbVie PARP inhibitor after double trial failure Veliparib fails in two phase 3 trials.
News AbbVie’s elagolix shows promise in uterine fibroids treatmen... AbbVie's elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for the pipeline drug, which could become a major earner for the company.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
